FolioLanternBeta
RVMDRevolution Medicines, Inc.

Mark Goldsmith

President and Chief Executive Officer, Director at Revolution Medicines, Inc., as of Sep 18, 2026Sold $57.0M of stock in the past 12 months: 100% under a disclosed plan.

Updated Oct 15, 2026 from SEC filings · covers Oct 16, 2025 to Oct 15, 2026
813K
shares held after the latest filing, Revolution Medicines, Inc.
Vested shares reported on Forms 3, 4 and 5 only. Not the insider's whole wealth.
450K
shares sold, past 12 months
13
days with sales
$18.0M
largest single day, Apr 15, 2026
1
company filed for

Share of stake sold at Revolution Medicines, Inc. is not shown: the holdings on record are not confirmed. Why

Selling by month

Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planOne dollar scale for every month; the tallest bar is labeled
Oct 2025: $1.1M under a disclosed planOctNov 2025: $9.5M under a disclosed planNovDec 2025: $1.2M under a disclosed planDecJanFebMar 2026: $4.9M under a disclosed planMarApr 2026: $18.0M under a disclosed plan$18.0MAprMayJun 2026: $1.6M under a disclosed planJunJulAug 2026: $18.0M under a disclosed planAugSep 2026: $2.8M under a disclosed planSepOct

Pattern

What the filings show, past 12 months. Nothing here rates or predicts.

Roles from filings

Every company we track where this person has filed, newest filing first.

CompanyTitleFirst filingLatest filing
Revolution Medicines, Inc. (RVMD)President and Chief Executive Officer, DirectorFeb 12, 2020Sep 18, 2026

Recent filings

The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.

This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.